You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCanagliflozin
Accession NumberDB08907
TypeSmall Molecule
GroupsApproved
Description

Canagliflozin belongs to a new class of anti-diabetic drugs that works by inhibiting the sodium-glucose transport protein (SGLT2). This transport protein is found in the kidney and is responsible for reabsorbing glucose that has been filtered. FDA approved on March 29, 2013.

Structure
Thumb
Synonyms
Canagliflozin anhydrous
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Invokanatablet100 mgoralJanssen Inc2014-06-03Not applicableCanada
Invokanatablet, film coated300 mg/1oralJanssen Pharmaceuticals, Inc.2013-03-29Not applicableUs
Invokanatablet, film coated100 mg/1oralJanssen Pharmaceuticals, Inc.2013-03-29Not applicableUs
Invokanatablet300 mgoralJanssen Inc2014-05-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
InvokametJanssen Pharmaceuticals, Inc.
Salts
Name/CASStructureProperties
Canagliflozin hydrate
928672-86-0
Thumb
  • InChI Key: VHOFTEAWFCUTOS-TUGBYPPCSA-N
  • Monoisotopic Mass: 906.291911168
  • Average Mass: 907.05
DBSALT001783
Categories
UNII6S49DGR869
CAS number842133-18-0
WeightAverage: 444.516
Monoisotopic: 444.140672805
Chemical FormulaC24H25FO5S
InChI KeyInChIKey=XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
InChI
InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1
IUPAC Name
(2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol
SMILES
[H][C@]1(O[[email protected]](CO)[C@@H](O)[[email protected]](O)[[email protected]]1O)C1=CC=C(C)C(CC2=CC=C(S2)C2=CC=C(F)C=C2)=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenolic glycosides. These are organic compounds containing a phenolic structure attached to a glycosyl moiety. Some examples of phenolic structures include lignans, and flavonoids. Among the sugar units found in natural glycosides are D-glucose, L-Fructose, and L rhamnose.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassGlycosyl compounds
Direct ParentPhenolic glycosides
Alternative Parents
Substituents
  • Phenolic glycoside
  • C-glycosyl compound
  • 2,5-disubstituted thiophene
  • Toluene
  • Halobenzene
  • Fluorobenzene
  • Benzenoid
  • Oxane
  • Monosaccharide
  • Monocyclic benzene moiety
  • Aryl halide
  • Aryl fluoride
  • Heteroaromatic compound
  • Thiophene
  • Secondary alcohol
  • Polyol
  • 1,2-diol
  • Oxacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Hydrocarbon derivative
  • Primary alcohol
  • Organofluoride
  • Organohalogen compound
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationCanagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Use in type 1 diabetes mellitus patients or in treatment of diabetic ketoacidosis is not recommended.
PharmacodynamicsCanagliflozin binds to SGLT2 more potently (250-times) than SGLT1 in vitro. The 50% inhibitory concentrations (IC50) are 2.2-4.4 nmol/L and 684 - 910 nmol/L for SGLT2 and SGLT1 respectively. Dose dependent decreases in renal threshold for glucose and increases in urinary glucose excretion were observed when single and multiple oral doses were administered to type 2 diabetes patients. Decreases in plasma glucose in a dose-dependent fashion were also noted as early as the first day of administration. When given to healthy and type 2 diabetic patients before a meal, a delay in intestinal glucose absorption and a reduction in postprandial glucose was observed. Canagliflozin does not prolong the QTc interval.
Mechanism of actionSodium-glucose co-transporter 2 (SGLT2), expressed in the proximal renal tubules, is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. Canagliflozin is an inhibitor of SGLT2. By inhibiting SGLT2, canagliflozin reduces reabsorption of filtered glucose and lowers the renal threshold for glucose (RTG), and thereby increases urinary glucose excretion.
Related Articles
AbsorptionThe pharmacokinetics of canagliflozin is similar in healthy subjects and patients with type 2 diabetes. Plasma Cmax and AUC of canagliflozin increased in a dose-proportional manner from 50 mg to 300 mg. Accumulation in plasma has been observed following multiple doses of 100 - 300 mg. Food does not affect the absorption of canagliflozin. Tmax = 1- 2 hours; Cmax = 1059 - 3148 ng/mL; Time to steady state, once daily dose, 100 - 300 mg = 4-5 days; Absolute oral bioavailability = 65%.
Volume of distribution

Steady state, single IV infusion, healthy subject = 119 L. This high value suggests that cangliflozin is extensively distributed to tissue.

Protein binding>99% protein bound, mainly to albumin. It also binds to alpha-acid glycoprotein. Protein binding is independent of canagliflozin plasma concentrations. Plasma protein binding is not meaningfully altered in patients with renal or hepatic impairment.
Metabolism

Canagliflozin is hepatically metabolized via O-glucuronidation into two inactive O-glucuronide metabolites. The enzymes that facilitate this process are UGT1A9 and UGT2B4. To a lesser extent (7%), canagliflozin also undergoes oxidative metabolism via CYP3A4. Canagliflozin weakly inhibited CYP2B6, CYP2C8, CYP2C9, and CYP3A4 based on in vitro studies with human hepatic microsomes.

Route of eliminationEnterohepatic circulation of canagliflozin was negligible. When a single oral dose is administered to a healthy subject, canagliflozin is eliminated via the following: Feces (41.5%, 7.0%, 3.2% as canagliflozin, a hydroxylated metabolite, and an O-glucuronide metabolite, respectively). Urine (33%; 30.5% as O-glucuronide metabolite, <1% as unchanged drug).
Half lifeThe apparent terminal half-life (t1/2) was 10.6 hours and 13.1 hours for the 100 mg and 300 mg doses, respectively.
Clearance

Mean systemic clearance, healthy subjects, IV administration = 192 mL/min.
Renal clearance of canagliflozin 100 mg and 300 mg doses ranged from 1.30 to 1.55 mL/min.

ToxicityMost common adverse reactions associated with canagliflozin (5% or greater incidence): female genital mycotic infections, urinary tract infection, and increased urination.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9541
Blood Brain Barrier+0.7708
Caco-2 permeable-0.6554
P-glycoprotein substrateSubstrate0.6058
P-glycoprotein inhibitor INon-inhibitor0.8414
P-glycoprotein inhibitor IINon-inhibitor0.9447
Renal organic cation transporterNon-inhibitor0.8544
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8293
CYP450 3A4 substrateNon-substrate0.5929
CYP450 1A2 substrateNon-inhibitor0.6579
CYP450 2C9 inhibitorNon-inhibitor0.6178
CYP450 2D6 inhibitorNon-inhibitor0.8683
CYP450 2C19 inhibitorNon-inhibitor0.5958
CYP450 3A4 inhibitorNon-inhibitor0.7086
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7691
Ames testNon AMES toxic0.584
CarcinogenicityNon-carcinogens0.9103
BiodegradationNot ready biodegradable0.9936
Rat acute toxicity2.5975 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9912
hERG inhibition (predictor II)Non-inhibitor0.7246
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedoral
Tabletoral100 mg
Tabletoral300 mg
Tablet, film coatedoral100 mg/1
Tablet, film coatedoral300 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7943582 No2009-02-262029-02-26Us
US7943788 No2007-07-142027-07-14Us
US8222219 No2004-07-302024-07-30Us
US8513202 No2007-12-032027-12-03Us
US8785403 No2004-07-302024-07-30Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0045 mg/mLALOGPS
logP3.09ALOGPS
logP3.52ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)12.57ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area90.15 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity116.14 m3·mol-1ChemAxon
Polarizability46.5 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]
External Links
ATC CodesA10BD16A10BX11
AHFS Codes
  • 68:20.18
PDB EntriesNot Available
FDA labelDownload (683 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetazolamideThe risk or severity of adverse effects can be increased when Acetazolamide is combined with Canagliflozin.
Acetylsalicylic acidAcetylsalicylic acid may increase the hypoglycemic activities of Canagliflozin.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Canagliflozin.
AliskirenCanagliflozin may increase the hyperkalemic activities of Aliskiren.
AmilorideCanagliflozin may increase the hyperkalemic activities of Amiloride.
ArdeparinArdeparin may increase the hyperkalemic activities of Canagliflozin.
AripiprazoleThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Aripiprazole.
Arsenic trioxideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Arsenic trioxide.
ArticaineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Articaine.
AsenapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Asenapine.
AtazanavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Atazanavir.
Azilsartan medoxomilCanagliflozin may increase the hyperkalemic activities of Azilsartan medoxomil.
BenazeprilCanagliflozin may increase the hyperkalemic activities of Benazepril.
BendroflumethiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Bendroflumethiazide.
BetamethasoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Betamethasone.
BrexpiprazoleThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Brexpiprazole.
BumetanideCanagliflozin may increase the hypotensive activities of Bumetanide.
BuserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Buserelin.
ButabarbitalButabarbital may increase the hypotensive activities of Canagliflozin.
ButethalButethal may increase the hypotensive activities of Canagliflozin.
CandesartanCanagliflozin may increase the hyperkalemic activities of Candesartan.
CaptoprilCanagliflozin may increase the hyperkalemic activities of Captopril.
CarbamazepineThe serum concentration of Canagliflozin can be decreased when it is combined with Carbamazepine.
CeritinibThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ceritinib.
ChlorothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorothiazide.
ChlorpropamideCanagliflozin may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Chlorthalidone.
CilazaprilCanagliflozin may increase the hyperkalemic activities of Cilazapril.
ClozapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Clozapine.
CorticotropinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Corticotropin.
Cortisone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cortisone acetate.
Cyproterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Cyproterone acetate.
DabrafenibThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dabrafenib.
DalteparinDalteparin may increase the hyperkalemic activities of Canagliflozin.
DanazolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Danazol.
DarunavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Darunavir.
DesogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Desogestrel.
DexamethasoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dexamethasone.
DiazoxideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Diazoxide.
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Canagliflozin.
DienogestThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Dienogest.
DihydrotestosteroneDihydrotestosterone may increase the hypoglycemic activities of Canagliflozin.
DisopyramideCanagliflozin may increase the hypoglycemic activities of Disopyramide.
DrospirenoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Drospirenone.
EfavirenzThe serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.
EnalaprilCanagliflozin may increase the hyperkalemic activities of Enalapril.
EnalaprilatCanagliflozin may increase the hyperkalemic activities of Enalaprilat.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Canagliflozin.
EpinephrineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Epinephrine.
EplerenoneCanagliflozin may increase the hyperkalemic activities of Eplerenone.
EprosartanCanagliflozin may increase the hyperkalemic activities of Eprosartan.
ErythromycinCanagliflozin may increase the hypoglycemic activities of Erythromycin.
EstradiolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estradiol.
Estrone sulfateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estropipate.
Etacrynic acidCanagliflozin may increase the hypotensive activities of Ethacrynic acid.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Canagliflozin.
Ethinyl EstradiolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethinyl Estradiol.
EthoxzolamideThe risk or severity of adverse effects can be increased when Ethoxzolamide is combined with Canagliflozin.
Ethynodiol diacetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ethynodiol.
EtonogestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.
EverolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Everolimus.
FludrocortisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fludrocortisone.
FosamprenavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Fosamprenavir.
FosinoprilCanagliflozin may increase the hyperkalemic activities of Fosinopril.
FosphenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Fosphenytoin.
FurosemideCanagliflozin may increase the hypotensive activities of Furosemide.
GliclazideCanagliflozin may increase the hypoglycemic activities of Gliclazide.
GlimepirideCanagliflozin may increase the hypoglycemic activities of Glimepiride.
GlipizideCanagliflozin may increase the hypoglycemic activities of Glipizide.
GlyburideCanagliflozin may increase the hypoglycemic activities of Glyburide.
GoserelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Goserelin.
HeparinHeparin may increase the hyperkalemic activities of Canagliflozin.
HeptabarbitalHeptabarbital may increase the hypotensive activities of Canagliflozin.
HexobarbitalHexobarbital may increase the hypotensive activities of Canagliflozin.
HistrelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Histrelin.
HydrochlorothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrochlorothiazide.
HydrocortisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydrocortisone.
Hydroxyprogesterone caproateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Hydroxyprogesterone caproate.
IloperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Iloperidone.
IndapamideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indapamide.
IndinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Indinavir.
Insulin AspartCanagliflozin may increase the hypoglycemic activities of Insulin Aspart.
Insulin DegludecCanagliflozin may increase the hypoglycemic activities of Insulin degludec.
Insulin DetemirCanagliflozin may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlargineCanagliflozin may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisineCanagliflozin may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanCanagliflozin may increase the hypoglycemic activities of Insulin Regular.
Insulin LisproCanagliflozin may increase the hypoglycemic activities of Insulin Lispro.
IrbesartanCanagliflozin may increase the hyperkalemic activities of Irbesartan.
LanreotideCanagliflozin may increase the hypoglycemic activities of Lanreotide.
LeuprolideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Leuprolide.
LevonorgestrelThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Levonorgestrel.
LisinoprilCanagliflozin may increase the hyperkalemic activities of Lisinopril.
LopinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lopinavir.
LosartanCanagliflozin may increase the hyperkalemic activities of Losartan.
LurasidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Lurasidone.
MecaserminCanagliflozin may increase the hypoglycemic activities of Mecasermin.
Medroxyprogesterone acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Medroxyprogesterone Acetate.
Megestrol acetateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Megestrol acetate.
MestranolThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Mestranol.
MethohexitalMethohexital may increase the hypotensive activities of Canagliflozin.
MethotrimeprazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methotrimeprazine.
MethyclothiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methyclothiazide.
MethylprednisoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Methylprednisolone.
MetolazoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Metolazone.
MifepristoneCanagliflozin may increase the hypoglycemic activities of Mifepristone.
MoexiprilCanagliflozin may increase the hyperkalemic activities of Moexipril.
NadololThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Canagliflozin.
NateglinideCanagliflozin may increase the hypoglycemic activities of Nateglinide.
NelfinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nelfinavir.
NiacinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Niacin.
NicorandilNicorandil may increase the hypotensive activities of Canagliflozin.
NilotinibThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Nilotinib.
NorethisteroneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norethindrone.
NorgestimateThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Norgestimate.
OctreotideCanagliflozin may increase the hypoglycemic activities of Octreotide.
OlanzapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Olanzapine.
OlmesartanCanagliflozin may increase the hyperkalemic activities of Olmesartan.
OxandroloneOxandrolone may increase the hypoglycemic activities of Canagliflozin.
PaliperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Paliperidone.
ParoxetineParoxetine may increase the hypoglycemic activities of Canagliflozin.
PasireotideCanagliflozin may increase the hypoglycemic activities of Pasireotide.
PentamidineCanagliflozin may increase the hypoglycemic activities of Pentamidine.
PentobarbitalPentobarbital may increase the hypotensive activities of Canagliflozin.
PerindoprilCanagliflozin may increase the hyperkalemic activities of Perindopril.
PhenelzinePhenelzine may increase the hypoglycemic activities of Canagliflozin.
PhenobarbitalThe serum concentration of Canagliflozin can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Canagliflozin can be decreased when it is combined with Phenytoin.
PipotiazineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Pipotiazine.
PrednisoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisolone.
PrednisoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisone.
PrimidonePrimidone may increase the hypotensive activities of Canagliflozin.
ProgesteroneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Progesterone.
QuetiapineThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Quetiapine.
QuinaprilCanagliflozin may increase the hyperkalemic activities of Quinapril.
QuinineCanagliflozin may increase the hypoglycemic activities of Quinine.
RamiprilCanagliflozin may increase the hyperkalemic activities of Ramipril.
RepaglinideCanagliflozin may increase the hypoglycemic activities of Repaglinide.
Repository corticotropinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Repository corticotropin.
RifampicinThe serum concentration of Canagliflozin can be decreased when it is combined with Rifampicin.
RisperidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Risperidone.
RitonavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ritonavir.
SaquinavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Saquinavir.
SecobarbitalSecobarbital may increase the hypotensive activities of Canagliflozin.
SirolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Sirolimus.
SparfloxacinSparfloxacin may increase the hypoglycemic activities of Canagliflozin.
SpironolactoneCanagliflozin may increase the hyperkalemic activities of Spironolactone.
St. John's WortThe serum concentration of Canagliflozin can be decreased when it is combined with St. John&#39;s Wort.
SulfadiazineCanagliflozin may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazoleCanagliflozin may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazoleCanagliflozin may increase the hypoglycemic activities of Sulfisoxazole.
SunitinibCanagliflozin may increase the hypoglycemic activities of Sunitinib.
TacrolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tacrolimus.
TelmisartanCanagliflozin may increase the hyperkalemic activities of Telmisartan.
TemsirolimusThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Temsirolimus.
TestosteroneTestosterone may increase the hypoglycemic activities of Canagliflozin.
TinzaparinTinzaparin may increase the hyperkalemic activities of Canagliflozin.
TipranavirThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Tipranavir.
TolazamideCanagliflozin may increase the hypoglycemic activities of Tolazamide.
TolbutamideCanagliflozin may increase the hypoglycemic activities of Tolbutamide.
TorasemideCanagliflozin may increase the hypotensive activities of Torasemide.
TrandolaprilCanagliflozin may increase the hyperkalemic activities of Trandolapril.
TranylcypromineTranylcypromine may increase the hypoglycemic activities of Canagliflozin.
TriamcinoloneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triamcinolone.
TriamtereneCanagliflozin may increase the hyperkalemic activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Trichlormethiazide.
TrimethoprimCanagliflozin may increase the hypoglycemic activities of Trimethoprim.
TriptorelinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Triptorelin.
ValsartanCanagliflozin may increase the hyperkalemic activities of Valsartan.
VorinostatThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Vorinostat.
ZiprasidoneThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Ziprasidone.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Low-affinity glucose:sodium symporter activity
Specific Function:
Sodium-dependent glucose transporter. Has a Na(+) to glucose coupling ratio of 1:1.Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A2
Uniprot ID:
P31639
Molecular Weight:
72895.995 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Glucose:sodium symporter activity
Specific Function:
Actively transports glucose into cells by Na(+) cotransport with a Na(+) to glucose coupling ratio of 2:1. Efficient substrate transport in mammalian kidney is provided by the concerted action of a low affinity high capacity and a high affinity low capacity Na(+)/glucose cotransporter arranged in series along kidney proximal tubules.
Gene Name:
SLC5A1
Uniprot ID:
P13866
Molecular Weight:
73497.275 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Retinoic acid binding
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks transferase activity but acts as a negative regulator of isoform 1.
Gene Name:
UGT1A9
Uniprot ID:
O60656
Molecular Weight:
59940.495 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGTs are of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isozyme is active on polyhydroxylated estrogens (such as estriol, 4-hydroxyestrone and 2-hydroxyestriol) and xenobiotics (such as 4-methylumbelliferone, 1-naphthol, 4-nitrophenol, 2-aminophenol, 4-hydroxybiphenyl and menthol). It is capable of 6 alpha-hydr...
Gene Name:
UGT2B4
Uniprot ID:
P06133
Molecular Weight:
60512.035 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Lamos EM, Younk LM, Davis SN: Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol. 2013 Jun;9(6):763-75. doi: 10.1517/17425255.2013.791282. Epub 2013 Apr 17. [PubMed:23590413 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
Comments
comments powered by Disqus
Drug created on June 17, 2013 00:21 / Updated on June 25, 2016 01:51